"Long-acting" olanzapine in maintenance therapy of schizophrenia: A study with plasma levels.
作者： Massimo C. Mauri , Michele Maffini , Chiara Di Pace , Alessandra Reggiori , Silvia Paletta
DOI: 10.3109/13651501.2014.1000928
关键词: Psychiatry 、 Every Two Months 、 Prospective cohort study 、 Olanzapine 、 Schizophrenia 、 Brief Psychiatric Rating Scale 、 Every Four Weeks 、 Maintenance therapy 、 Medicine 、 Tolerability
摘要: AbstractIntroduction. This prospective study was performed to evaluate clinical efficacy and tolerability of olanzapine long-acting injection (OLZ-LAI) the relation between OLZ plasma level (PL) outcome in maintenance therapy schizophrenia. Material methods. Twenty-five chronic schizophrenic outpatients with age ranging from 18 65 years were included this 9-month study. Patients given a dosage either 210 or 300 405 mg OLZ-LAI every 28 days. evaluated at baseline four weeks by Brief Psychiatric Rating Scale (BPRS) Positive Negative Symptom (PANSS); same time, PL determined. The metabolic profile (aspartate aminotransferase, alanine high-density lipoprotein, low-density total cholesterol, glucose levels) analyzed two months. Results. BPRS PANSS showed statistically significant improvement T2 stabilization psychopathological p...
elsevier.com
sci-hub.se 参考文章(27)
W Wolfgang Fleischhacker, Ireneus PM Keet, René S Kahn, EUFEST Steering Committee, The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. Schizophrenia Research. ,vol. 78, pp. 147- 156 ,(2005) , 10.1016/J.SCHRES.2005.06.004
Vladan Novakovic, Tymaz Adel, Eric Peselow, Jean-Pierre Lindenmayer, Long-Acting Injectable Antipsychotics and the Development of Postinjection Delirium/Sedation Syndrome (PDSS) Clinical Neuropharmacology. ,vol. 36, pp. 59- 62 ,(2013) , 10.1097/WNF.0B013E3182854F70
Malcolm Mitchell, Prajakti Kothare, Richard Bergstrom, Fangyi Zhao, Kai Yu Jen, Daniel Walker, Jason Johnson, David McDonnell, Single- and Multiple-Dose Pharmacokinetic, Safety, and Tolerability Profiles of Olanzapine Long-Acting Injection: An Open-Label, Multicenter, Nonrandomized Study in Patients With Schizophrenia Clinical Therapeutics. ,vol. 35, pp. 1890- 1908 ,(2013) , 10.1016/J.CLINTHERA.2013.09.023
Noam Y. Kirson, Peter J. Weiden, Sander Yermakov, Wayne Huang, Thomas Samuelson, Steve J. Offord, Paul E. Greenberg, Bruce J. O. Wong, Efficacy and Effectiveness of Depot Versus Oral Antipsychotics in Schizophrenia: Synthesizing Results Across Different Research Designs The Journal of Clinical Psychiatry. ,vol. 74, pp. 568- 575 ,(2013) , 10.4088/JCP.12R08167
Jørn Lykke, Morten Hesse, Stephen Fitzgerald Austin, Irene Oestrich, Validity of the BPRS, the BDI and the BAI in dual diagnosis patients Addictive Behaviors. ,vol. 33, pp. 292- 300 ,(2008) , 10.1016/J.ADDBEH.2007.09.020
Holland C Detke, Fangyi Zhao, Michael M Witte, Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data BMC Psychiatry. ,vol. 12, pp. 51- 51 ,(2012) , 10.1186/1471-244X-12-51
Diego Novick, Josep Maria Haro, David Suarez, Victor Perez, Ralf W. Dittmann, Peter M. Haddad, Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Research-neuroimaging. ,vol. 176, pp. 109- 113 ,(2010) , 10.1016/J.PSYCHRES.2009.05.004
Diana O. Perkins, Hongbin Gu, Peter J. Weiden, Joseph P. McEvoy, Robert M. Hamer, Jeffrey A. Lieberman, Predictors of Treatment Discontinuation and Medication Nonadherence in Patients Recovering From a First Episode of Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder : A Randomized, Double-Blind, Flexible-Dose, Multicenter Study The Journal of Clinical Psychiatry. ,vol. 69, pp. 106- 113 ,(2008) , 10.4088/JCP.V69N0114
Holland C Detke, David P McDonnell, Elizabeth Brunner, Fangyi Zhao, Sebastian Sorsaburu, Victoria J Stefaniak, Sara A Corya, Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases BMC Psychiatry. ,vol. 10, pp. 43- 43 ,(2010) , 10.1186/1471-244X-10-43
David P. Mcdonnell, Scott W. Andersen, Holland C. Detke, Fangyi Zhao, Susan B. Watson, Long-Term Safety and Tolerability of Open-Label Olanzapine Long-Acting Injection in the Treatment of Schizophrenia: 190-Week Interim Results Clinical Medicine Insights: Psychiatry. ,vol. 2011, pp. 37- 47 ,(2011) , 10.4137/CMPSY.S6659